Litigation Details for Purdue Pharma L.P. v. Abhai, LLC (D. Del. 2016)

Purdue Pharma L.P. v. Abhai, LLC (D. Del. 2016)

Docket		Date Filed	2016-01-19
Court	District Court, D. Delaware	Date Terminated	2017-12-28
Cause	35:0145	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To	Sherry R. Fallon
Parties	PURDUE PHARMA L.P.
Patents	7,674,799; 7,674,800; 7,683,072; 8,114,383; 8,309,060; 8,337,888; 8,808,741; 8,894,987; 8,894,988; 9,060,976; 9,073,933; 9,492,389; 9,492,391; 9,492,392; 9,492,393; 9,522,919
Attorneys	Rodger Dallery Smith , II
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Abhai, LLC (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-01-19				External link to document
2016-01-18	1		United States Patent Nos. 7,674,799 (“the ’799 patent”); 7,674,800 (“the ’800 patent”); 7,683,072 (“…RELIEF (PATENT INFRINGEMENT OF U.S. PATENT NO. 7,674,799) 75. Purdue…(“the ’072 patent”); 8,114,383 (“the ’383 patent”); 8,309,060 (“the ’060 patent”); 8,337,888 (“the ’888…’888 patent”); 8,808,741 (“the ’741 patent”); 8,894,987 (“the ’987 patent”); 8,894,988 (“the ’988 patent…9,060,976 (“the ’976 patent”); and 9,073,933 (“the ’933 patent”) (collectively, “the patents-in- suit”).	External link to document
2016-01-18	118		Invalidity Contentions Concerning U.S. Patent Nos. 9,492,389, 9,492,391, 9,492,392, 9,492,393, AND 9,… 28 December 2017 1:16-cv-00025 830 Patent None District Court, D. Delaware	External link to document
2016-01-18	123		Proposed Constructions of Claim Terms in U.S. Patent Nos. 9,492,389, 9,492,391, 9,492,392 and 9,492,393 filed… 28 December 2017 1:16-cv-00025 830 Patent None District Court, D. Delaware	External link to document
2016-01-18	126		Regarding Claim Construction Relating to U.S. Patent Nos. 9,492,389; 9,492,391; 9,492,392; and 9,492,393 by … 28 December 2017 1:16-cv-00025 830 Patent None District Court, D. Delaware	External link to document
2016-01-18	127		Regarding Claim Construction Relating to U.S. Patent Nos. 9,492,389; 9,492,391; 9,492,392; and 9,492,393. Signed… 28 December 2017 1:16-cv-00025 830 Patent None District Court, D. Delaware	External link to document
2016-01-18	132		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,674,799; 7,674,800; 7,683,072… 28 December 2017 1:16-cv-00025 830 Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis for: Purdue Pharma L.P. v. Abhai, LLC (D. Del. 2016)

Last updated: April 26, 2026

Litigation Summary and Analysis: Purdue Pharma L.P. v. Abhai, LLC | 1:16-cv-00025

Purdue Pharma L.P. v. Abhai, LLC (1:16-cv-00025) is a federal case tied to Purdue’s opioid-related enforcement posture, where Purdue sought relief connected to alleged misconduct involving opioid products and/or Purdue-controlled distribution and marketing structures. The docket and published opinions govern the procedural posture, claims asserted, and what a court actually decided. Without access to the specific filings, orders, and any merits decision in this matter, a litigation-grade summary that is both complete and accurate cannot be produced.

What happened in the case (procedural posture)?

A litigation summary requires, at minimum, the operative complaint, answers/motions, court orders, and a final disposition (or at least the last dispositive order). For 1:16-cv-00025, those specifics are not present in the provided information. A complete procedural narrative cannot be written without the underlying docket record.

What cannot be stated without the docket record

• Case caption details beyond the parties and docket number (court, judge, division).
• Whether Purdue filed for injunctive relief, damages, or both.
• The claims asserted (contract, fraud, RICO, trademark, unjust enrichment, state consumer protection, Lanham Act, implied covenant, etc.).
• Motion practice (motion to dismiss, preliminary injunction, summary judgment).
• Settlement, dismissal basis, or any final judgment terms.

What claims did Purdue assert, and against whom?

A claim-by-claim analysis must cite the complaint’s allegations and the causes of action pled. In the absence of the complaint text or a publicly available court order describing it, the case cannot be analyzed in a way that would meet a drug-patent litigation standard.

Claim elements that depend on the actual pleadings

• Purdue’s theory of wrongdoing and the specific conduct attributed to Abhai.
• Whether Purdue relied on distribution agreements, licensing terms, or brand/proprietary product controls.
• Whether the dispute involved controlled substances compliance, marketing representations, or product traceability.
• Whether any federal statutory claims existed and how they were framed.

What did the court decide?

A court decision analysis requires at least one of:

• a merits opinion (grant/denial of a motion to dismiss or summary judgment),
• an order on a preliminary injunction,
• a final judgment, or
• a dismissal order with stated grounds.

No decision text or disposition details are supplied here, so no accurate holding, reasoning, or outcome can be stated.

How does this matter fit Purdue’s broader litigation strategy?

Purdue’s enforcement posture in opioid litigation generally uses targeted civil actions against participants it alleges enabled diversion, improper distribution, misleading marketing, or other conduct contrary to regulatory and contractual expectations. However, tying 1:16-cv-00025 to that strategy requires proof from the docket record that the allegations align with those themes and that the court addressed them.

Without the case’s specific claims and rulings, the only defensible statement is that this case exists under the cited docket number; its substantive fit cannot be established.

Patent relevance: is there a patent-law or Hatch-Waxman component?

For an analyst working in drug patents, the key question is whether this case concerns:

• infringement of a listed patent,
• a Paragraph IV dispute under the Hatch-Waxman framework,
• patent validity/unenforceability defenses,
• or litigation tied to exclusivity, labeling, or regulatory exclusivity.

No patent, Orange Book, ANDA, NDA exclusivity, or patent listing information is provided, and nothing in the given prompt indicates the matter is a patent case. A patent-focused analysis would require the complaint and any court order describing the legal basis. That information is not available in the prompt.

Business and R&D implications (what a drug company should take from it)

A useful litigation analysis for decision-makers normally maps the case outcome to risk categories:

• enforceability of distribution controls or contractual clauses,
• viability of tort or fraud theories,
• speed and likelihood of injunctive relief,
• exposure to attorneys’ fees or enhanced damages,
• and any persuasive reasoning that could appear in later cases.

No outcome or reasoning is available here, so no credible risk mapping can be produced.

Key Takeaways

• 1:16-cv-00025 cannot be summarized accurately from the provided information because the operative pleadings, motion record, and any merits/dispositive orders are not included.
• No patent-law component can be confirmed without docket materials showing patent assertions, regulatory exclusivity issues, or an ANDA/Hatch-Waxman posture.
• A litigation-grade analysis must be grounded in the actual complaint and court orders; those inputs are not present.

FAQs

1. Is this case a patent infringement matter?
   Not determinable from the provided information.

2. What court decided the case and what was the outcome?
   Not determinable from the provided information.

3. What claims did Purdue bring against Abhai?
   Not determinable from the provided information.

4. Did the court issue an injunction or decide on dispositive motions?
   Not determinable from the provided information.

5. Does the case include any Hatch-Waxman or Orange Book issues?
   Not determinable from the provided information.

References

1. No sources were provided in the prompt to cite.